Alemtuzumab for refractory celiac disease [23]

New England Journal of Medicine

Volumn 355, Issue 13, 2006, Pages 1396-1397

  Verbeek, Wieke H M ^a   Mulder, Chris J J ^a   Zweegman, Sonja ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; CLADRIBINE; PREDNISONE;

AGED; ANTIGEN EXPRESSION; CASE REPORT; CELIAC DISEASE; DRUG TARGETING; DUODENUM BIOPSY; FEMALE; FLOW CYTOMETRY; GLUTEN FREE DIET; HUMAN; HUMAN TISSUE; INTESTINE VILLUS ATROPHY; LETTER; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELIAC DISEASE; FEMALE; HUMANS; T-LYMPHOCYTES;

EID: 33749058804     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061784     Document Type: Letter

References (4)

1. Vivas S, Ruiz de Morales JM, Ramos F, Suárez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006;354:2514-5.
2. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 2000;356:203-8.
3. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005;19:413-24.
4. Lundin KE, Farstad IN, Raki M, Benestad Y, Hoie O, Tjonnfjord G. Alemtuzumab treatment of refractory celiac disease type II. Gastroenterology 2006;130:Suppl 2:A-666. abstract.